Cagrilintide
November 20, 2024Major Finding
7/10
Purrptide digest
While everyone was busy obsessing over GLP-1, Novo Nordisk quietly built an amylin analogue that hits a completely different fullness switch. Paired with Semaglutide (the combo is called CagriSema), early trial results pushed past 20% weight loss — beating Semaglutide alone by a wide margin. Amylin slows stomach emptying and tells your brain you're satisfied, which stacks nicely on top of GLP-1's appetite suppression. Two signals, same goal, different doors.
What this means for you
🏃
If you care about weight/health
If you've plateaued on Semaglutide alone, this combo is the upgrade path worth watching for approval.
🩺
If you're a clinician
Amylin and GLP-1 combos are the next obvious step in obesity pharmacology. Expect this conversation with patients soon.
🔬
If you're a researcher
The amylin/GLP-1 synergy is mechanistically clean — two non-overlapping satiety pathways. That's rarer than it sounds.
💸
If you follow biotech
Novo's answer to Lilly's Retatrutide. The weight-loss drug arms race just got a third major contender.
LA
Lau et al.
Novo Nordisk
For the nerds
Once-Weekly Cagrilintide for Weight Management
New England Journal of Medicine · DOI: 10.1056/NEJMoa2106918
Read full paper on PubMed →